Share on LinkedInShare on LinkedIn

ARTICLE · 23 JANUARY 2024

USPTO Issues "Reasonable" Guidance On Enablement Under Amgen V. Sanofi

The USPTO has issued "Guidelines for Assessing Enablement in Utility Applications and Patents in View of the Supreme Court Decision in Amgen Inc. et al. v. Sanofi et al."

United StatesIntellectual Property

The USPTO has issued "Guidelines for Assessing Enablement in Utility Applications and Patents in View of the Supreme Court Decision in Amgen Inc. et al. v. Sanofi et al." The Guidelines set forth the U.S. Patent and Trademark Office's (USPTO's) stance that the Supreme Court decision applies across the board without regard to technology, and instruct USPTO personnel to continue to use the Wands factors when assessing enablement. While the Guidelines mirror the Supreme Court's consideration of whether only a "reasonable" amount of experimentation would be required to practice the full scope of the claims instead of Wands' focus on an "undue amount of experimentation," the substantive standards appear to be unchanged.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from